Treats Human Immunodeficiency Virus (HIV-1) infection. ANDA 90092, held by Hetero Labs Ltd Iii. Zidovudine.
As of Nov 21, 2026, ANDA 90092 (Zidovudine), held by Hetero Labs Ltd Iii, was first approved by FDA on Apr 25, 2008, with 5 approved supplements and 0 published complete response letters.
Zidovudine tablets are a nucleoside analogue reverse transcriptase inhibitor indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 25, 2008 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Zidovudine300MG · tablet;oral | Zidovudine | Rx |
| Feb 10, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 10, 2020 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 10, 2020 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 25, 2010 | Supplement 2Labeling | Approved | None posted |
| Mar 5, 2009 | Supplement 1Labeling | Approved | None posted |
| Apr 25, 2008 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters